TPOXX® Antiviral Treatment (Tecovirimat)

A Contract Award Notice
by DEPARTMENT OF HEALTH AND SOCIAL CARE (DHSC)

Source
Contracts Finder
Type
Contract (Products)
Duration
1 year
Value
£1
Sector
HEALTH
Published
04 Nov 2022
Delivery
28 Jul 2022 to 27 Jul 2023
Deadline
27 Jul 2022 11:00

Concepts

Location

Geochart for 1 buyers and 1 suppliers

1 buyer

1 supplier

Description

The monkeypox virus belongs to a family of viruses called orthopox viruses and the drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. In the current outbreak, Tecovirimat has been successfully used to treat patients with the most severe presentations of monkeypox virus infection. This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of Monkeypox in the UK.

Award Detail

1 Meridian Medical Technologies (Belfast)
  • Value: £1

CPV Codes

  • 33651400 - Antivirals for systemic use

Other Information

MMT - UKDHSC TPOXX Conditions of Contract 27072022 _Redacted 03112022 MMT - UKDHSC TPOXX Conditions of Contract 27072022 _Redacted 03112022.pdf

Reference

Domains